India’s Specialty Chemicals Company That Dreamed Too Big Too Soon

The Company That Wanted to Be Five Companies at Once

Meet Archean Chemical Industries. Founded in 2009, listed in November 2022, and already starring in what can only be described as a multi-act Bollywood drama where the hero tries to save three businesses simultaneously while starting a fourth that nobody asked for.

The core business? Bromine, industrial salt, and sulphate of potash (SOP). Boringly profitable for 15 years. Ranking #1 in bromine exports globally. The company sits on 240 square kilometres of salt pans and brine reserves in Kutch, Gujarat — basically an infinite cash printer in normal times. Then 2023 happened. Bromine prices crashed 35%. Industrial salt followed. Margins vaporised. Management panicked.

And so began the Great Diversification Fever of 2024-2026. Three subsidiaries got set up to make bromine derivatives (Acume), mud chemicals for oil drilling (Idealis), and now — the pièce de résistance — a silicon carbide semiconductor fab (SiCSem). That’s right. A salt-and-bromine company is now trying to become Intel’s Indian cousin. With ₹2,067 crore. And government funding that hasn’t fully locked in yet.

The concall transcript from February 2026 reads like a management team on coffee overdose, switching between “bromine backlog is healthy” and “semiconductor commissioning timeline is still fluid” faster than a Virat Kohli cover drive. Meanwhile, the stock sits at P/E 50x, dividend yield 0.51%, and ROCE at a concerning 12.8%.

CRISIL just downgraded the outlook to Negative. The IT Department showed up in September 2025 for a “search.” New MD arrived January 2026. CFO quietly resigned. This is not a boring story. This is a case study in strategic ambition meeting operational chaos.

Bromine. Salt. And Dreams of Silicon.

Archean’s core business is integrated production of three chemicals from sea brine. The facility in Hajipir, Gujarat, sits atop brine reserves of ~240 sq km. Feed the brine through different processes, and out comes three products. Economics of scale scream “stay focused.” Archean heard “go diversify.”

Bromine (Segment A, ~34% revenue in FY25): Used in pharma, agrochemicals, water treatment, flame retardants, oil & gas, batteries. Archean exports mostly to China, with the balance sold domestically. Has 228 ISO containers (nickel/lead-lined, because bromine eats through regular metal like a Bombay beggar eats pav-bhaji). Capacity: 42,500 MTPA. Utilisation: Currently at maybe 70% because weather keeps messing with brine quality and plant operations keep getting disrupted. Management’s own language: “Flooding and weather changes have meant that brine quality… has changed in terms of composition.” Translation: Kutch got rained on. A lot.

Industrial Salt (Segment B, ~65% revenue in FY25): Exported to Japan, South Korea, China. Used in chlorine-caustic soda production, chemical industry, food & beverage. Capacity: 3,000,000 MTPA (then expanded to 6,000,000 MTPA — yes, doubled). Main customer: Sojitz Corporation, taking 50-55% of salt revenues. Long-term contracts. Boring. Profitable. Gets destroyed by monsoons (like when Cyclone Asna hit in Q2 FY25 and wiped out ₹40 crore of production). Management’s exact words on cyclone losses: “Cyclonic storm Asna hitting the Kutch region hard.”

SOP (Segment C, <1% revenue in FY25): Potassium sulphate. Specialty fertiliser for chlorine-sensitive crops. Archean is India’s only manufacturer from natural sea brine. Currently making 71 tons a quarter. Revenue: ₹32 lakhs. The company is aware this is an embarrassment. Management is trying to fix complex technical issues related to “feedstock variability” and has engaged a German technology partner. Plant-scale trials are underway. Revenue contribution: still a rounding error. Don’t expect meaningful contribution until FY27 “latter half,” per management.

Bromine Derivatives via Acume (Subsidiary #1): Clear brine fluids (CBF) and PTA catalyst (HBr) for oil drilling and chemical synthesis. Phase 1 commissioned March 2024. Running at 30-40% utilisation. Management admits being “12 to 18 months behind” schedule. Q3 FY26 revenue: ₹142 crore (consolidated only; not separately disclosed for derivatives alone). Why so low utilisation? Bromine feedstock costs went up (because bromine prices stayed firm). Customer qualification cycles are slow. Only 3-5 products driving most volumes — concentration risk that management is actively trying to diversify away from. Flame retardants (Phase 2) still in planning; earliest start is FY26, but language is soft: “not on hold,” but “project evaluation phase.”

Mud Chemicals via Idealis (Subsidiary #2): Acquired via NCLT in January 2024 for ₹77 crore from a company that hadn’t run for 4-5 years. Six facilities across Tamil Nadu, Andhra Pradesh, Gujarat. Used in oil drilling. Complements CBF. Currently being refurbished. ₹12 crore spent in FY25. Expected ₹20-30 crore in FY26. Peak historical revenue: ₹400-450 crore with 10-12% margins. Current revenue: nil. Profitability: negative (refurbishment losses). Management hopes to start operations at Gujarat plant by “H2 current fiscal.” We’re in February 2026, so that’s a 2-4 month window to restore a shuttered facility. Pray for them.

Semiconductors via SiCSem (Subsidiary #3): Silicon carbide MOSFETs/compound semiconductors. Annual capacity: 60,000 wafers, 96 million units (packaging). Project cost: ₹2,067 crore. Archean funds 25%. Government of India + Government of Odisha fund 75% (pari-passu). Technology partner: Clas-SiC Wafer Fab Ltd (UK). Archean invested GBP 12.5 million (~₹135 crore) plus GBP 2.5 million as a loan. Still in financial closure. Construction timeline: 2-2.5 years. Revenue contribution: fiscal 2029 onwards (at best). CRISIL’s summary: “Project-related risks remain elevated and will bear watching.” Translation: This is a moonshot. If it works, great. If not, well.

Q3 FY26: The Margin Squeeze is Real